Recovery and processing of human embryos formed in vivo

• US 9,561,257 B2
• Filed: 07/30/2015
• Issued: 02/07/2017
• Est. Priority Date: 12/22/2011
• Status: Active Grant

• Current Assignee: Butterfly Biosciences Incorporated
• Original Assignee: Previvo Genetics, LLC
• Inventors: Carson, Sandra Ann, Buster, John E., Cesario, Moses, Woodard, Steven Paul
• Primary Examiner(s): MATTHEWS, CHRISTINE HOPKINS
• Application Number:
  US14/814,151
• Publication Number:
  US 20150335700A1
• Time in Patent Office: 558 Days
• US Class Current: 1/1
• CPC Class Codes: A61B 17/42 Gynaecological or obstetrical instruments or methods ligaturing clamps or clips for the umbilical cord A61B17/122; curettage A61B17/320708; dilators A61M29/00
• CPC Class Codes: A61B 17/425 for reproduction or fertilisation specially adapted for use with animals A61D19/00
• CPC Class Codes: A61B 17/435 for embryo or ova transplantation
• CPC Class Codes: A61B 2017/4216 Operations on uterus, e.g. endometrium
• CPC Class Codes: A61B 2050/185 Drawers
• CPC Class Codes: A61B 2050/3008 having multiple compartments
• CPC Class Codes: A61B 2050/3011 having carrying handles
• CPC Class Codes: A61B 2050/311 Cases
• CPC Class Codes: A61B 2217/005 with suction drainage system
• CPC Class Codes: A61B 2217/007 with irrigation system
• CPC Class Codes: A61B 50/13 Trolleys, e.g. carts
• CPC Class Codes: A61B 50/20 Holders specially adapted for surgical or diagnostic appliances or instruments drapes with means to hold surgical instruments A61B46/23; for catheters A61M25/02
• CPC Class Codes: A61B 50/31 Carrying cases or bags, e.g. doctors' bags
• CPC Class Codes: A61K 31/215 of carboxylic acids
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 31/575 substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• CPC Class Codes: A61K 31/58 containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
• CPC Class Codes: A61K 38/08 Peptides having 5 to 11 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 38/09 Luteinising hormone-releasing hormone [LHRH] , i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
• CPC Class Codes: A61K 38/24 : Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
• CPC Class Codes: A61K 45/06 : Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/26 : Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• CPC Class Codes: A61K 9/0034 : Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
• CPC Class Codes: A61P 15/08 : for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• CPC Class Codes: C12Q 1/6883 : for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/156 : Polymorphic or mutational markers

Abstract

A kit having instructions for use for performing uterine lavage in a female patient includes a uterine lavage catheter configured for insertion into a woman'"'"'s uterus to remove viable blastocysts from the uterus, and one or more first containers having a sufficient dosage amount of a GnRH antagonist to cause desynchronization of the endometrium of the patient prior to, during and/or following recovery of viable blastocysts from the uterus.

Claims

1. A method of inducing corpus luteum apoptosis leading to desynchronization of the endometrium in a female patient, comprising recovering blastocysts and administering a GnRH antagonist to the patient such that corpus luteum apoptosis is induced wherein the GnRH antagonist is administered daily for up to ten days or until the onset of menses following blastocyst recovery to induce said corpus luteum apoptosis.

2. The method of claim 1, further including administering the GnRH antagonist on the day in which the blastocysts are recovered.

3. The method of claim 1, wherein the GnRH antagonist is administered at a dosage amount of about 0.10 to 400.0 mg.

4. The method of claim 1, wherein the GnRH antagonist is administered at a dosage amount of about 0.5 to 10.0 mg.

5. The method of claim 1, wherein the GnRH antagonist is administered at a dosage amount of about 0.5 to 5.0 mg.

6. The method of claim 1, wherein the GnRH antagonist is administered at a dosage amount of about 0.25 to 3.0 mg.

7. The method of claim 1, wherein the GnRH antagonist is administered at a dosage amount of about 3.0 mg.

8. The method of claim 1, further comprising administering a progesterone receptor antagonist to the patient.

9. The method of claim 8, wherein the progesterone receptor antagonist comprises a dosage of about 600 mg.

10. The method of claim 8, wherein the progesterone receptor antagonist comprises a dosage of between 100 to 200 mg.

11. The method of claim 8, wherein the progesterone receptor antagonist comprises Org31710 at a dosage of between 10 to 75 mg.

12. A method for inducing corpus luteum apoptosis leading to desynchronization of the endometrium following recovery of blastocysts from the uterus of a patient, the method comprising administering a GnRH antagonist in a pharmaceutically acceptable carrier at a dosage amount of about 0.5 to 400 mg to the patient after superovulation daily for up to ten days or until the onset of menses following blastocyst recovery to induce corpus luteum apoptosis.

13. A method of inducing corpus luteum apoptosis leading to desynchronization of the endometrium in a female patient, comprising recovering blastocysts and administering a GnRH antagonist to the patient on the day in which the blastocysts are recovered such that corpus luteum apoptosis is induced.